Skip to Main Content
Phase I

Imaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO

  • Study HIC#:2000021287
  • Last Updated:11/11/2022

We are conducting a PET imaging study to develop a way to measure the number of insulin secreting cells in the pancreas. This study is intended for people diagnosed with Type 2 Diabetes who are otherwise in good physical health and well controlled on insulin. The study requires 2-3 visits over several weeks.

  • Age18 years - 65 years
  • GenderBoth
  • Start Date09/05/2017
  • End Date07/31/2021

Trial Purpose and Description

As per HIC-approved protocol, 1411014915 (Specific Aim 1), this proposal will continue to explore whether an imaging agent already in use for human neuroimaging, specifically 11C-PHNO, would also be useful for measuring BCM.

Eligibility Criteria

Ages 18-65 (males and females) -Type 2 Diabetes diagnosis -Body mass index (BMI) of 18-35 kg/m2 -Not claustrophobic -Not taking anticoagulant medication Healthy controls are welcome 

Principal Investigator


For more information about this study, contact:

Or contact the Help us Discover team on: